الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Egypt, a lower middle-income country with a population of 100
million, had one of the highest burdens of HCV infections globally (Blach
et al., 2017). By 2018, the program had evolved into a national strategy to
eliminate HCV as a public health threat. This new strategy aligned with the
first Global Health Sector Strategy on Viral Hepatitis 2016–2021 agenda
that was unanimously adopted by the 194 World Health Organization
(WHO) member states, including Egypt.4 WHO signatories committed to
eliminating viral hepatitis as a public health threat by 2030. Elimination
was defined by WHO as a 65% reduction in mortality and a 90% reduction
in incidence, compared with the 2015 baseline (Organization 2016).
During the past few years, there have been enormous efforts to
understand the structure and life cycle of hepatitis C virus (HCV) and to
develop specific medications targeting different viral proteins such as
NS3/4A protease, NS5B polymerase, and NS5A replication complex. The
discovery of direct acting antiviral agents (DAAs) represented a revolution
in the management of chronic hepatitis C virus infection.
The aim of the present study was to assess Prevalence and predictors
of HCV relapse after direct acting antiviral drugs.
The present study was retrospective study, data were analyzed from
422 consecutive patients with HCV, who were selected from those
attending viral hepatitis C unit at Shebin El-khom teaching Hospital, Egypt
from (March 2019 to March 2020).
Patients were categorized to two group after assessment of
Eligibility of each patient for treatment of hepatitis C with DAAs according to the guidelines of the NCCVH
group (1): Easy-to-treat patients :
- Patients who were treatment naïve and had no cirrhosis or had normal
liver tests .
- They were treated with SOF-DCV for 12 weeks without RBV.
group (2): Difficult-to-treat patients:
- Patients who had previously failed interferon or SOF-based therapy,
patients with cirrhosis, and those who had serum albumin <3.5 g/dL,
bilirubin >1.2 mg/dL, INR>1.2 and/or platelet count <150 000/cmm.
They were treated with SOF-DCV-RBV for 12 weeks.
All patients in the present study were subjected to history taking, full
clinical examination, laboratory data (liver function profiles, prothrombin
time (PT), renal function tests, complete blood count, serum alpha
fetoprotein (AFP) and viral markers), Imaging data (Abdominal
ultrasonography and Triphasic CT).